Main menu

CyclomicsSeq: targeted and genome-wide detection of circulating tumor DNA using nanopore consensus sequencing

Get startedSubscribe
Return to Resources

Wigard Kloosterman, Cyclomics, demonstrated how CyclomicsSeq can facilitate the detection of mutations with a frequency of at least 0.02% in cfDNA in blood. He also discussed its potential for minimally-invasive presymptomatic screening in the future.

Authors: Wigard Kloosterman
Cancer Research Symposium
  • Published on: April 6 2022

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

お問い合わせ

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

Oxford Nanoporeについて

Contact us 経営陣 メディアリソース & お問い合わせ先 投資家向け Oxford Nanopore社で働く BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust

© 2008 - 2023 Oxford Nanopore Technologies plc. All rights reserved. 登記された事務所：Gosling Building,\n Edmund Halley Road, Oxford Science Park, OX4 4DQ, UK {'|'} 登記番号：05386273 {'|'} VAT番号：336942382。Oxford\n Nanopore Technologies、Wheel icon、EPI2ME、Flongle、GridION、Metrichor、MinION、MinIT、MinKNOW、Plongle、\n PromethION、SmidgION、UbikおよびVolTRAXは様々な国で登録されたOxford Nanopore Technologies\nの商標です。Oxford Nanopore Technologies製品は、\n現在すべて研究用です。

Japanese flag